Pulmonx Corp

In a Stage 4 decline featuring persistent lower highs and lower lows, the medium-term bias remains bearish under declining EMAs and distribution volume. Short-term timing is neutral as price tightly tracks flat EMAs and is oversold, suggesting risk of a bounce. Therefore, execution is deferred with a Trim approach, awaiting stalled rallies into structural resistance.

• ↑Maintains 2026 revenue guidance of $90–92M, targeting sequential quarterly improvement
• ↑Aims for 70,000+ first-time patient engagements in 2025 via DTP campaigns
• ↓Q1 revenue down 9% YoY to $20.6M; U.S. fell 7%, international down 12%